Dimethyl fumarate achieves no evidence of disease activity..

Discuss Tecfidera (BG-12, dimethyl fumarate) as an oral treatment for multiple sclerosis.

Dimethyl fumarate achieves no evidence of disease activity..

Postby MSUK » Fri Apr 21, 2017 2:38 am

Dimethyl fumarate achieves no evidence of disease activity in MS patients

Data analysis of two previous trials has shown that a higher number of patients with relapsing remitting multiple sclerosis (RRMS) achieved no evidence of disease activity (NEDA), over a two year period, with delayed-release dimethyl fumarate (DMF) compared to a placebo...Read more - http://www.ms-uk.org/dimethyl-fumarate-achieves-no-evidence-disease-activity-ms-patients-210417
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2830
Joined: Wed Oct 14, 2009 3:00 pm

Advertisement

Re: Dimethyl fumarate achieves no evidence of disease activi

Postby ElliotB » Fri Apr 21, 2017 8:23 am

The title of this post is inaccurate and deceiving.



The purpose of the study was "to evaluate the effect of DMF on achieving no evidence of disease activity (NEDA) "

And actually, the conclusion of the study was:

"A significantly higher percentage of patients treated with DMF achieved NEDA status over 2 years compared with placebo."

Here is a link to the study:

https://www.ncbi.nlm.nih.gov/pubmed/28328179


Per MSUK's own release:

Data analysis of two previous trials has shown that a higher number of patients with relapsing remitting multiple sclerosis (RRMS) achieved no evidence of disease activity (NEDA), over a two year period, with delayed-release dimethyl fumarate (DMF) compared to a placebo.




In any case, the results seem somewhat favorable anyway. Copaxone was also used in the study and had very similar results.
ElliotB
Family Elder
 
Posts: 1113
Joined: Mon Feb 03, 2014 5:08 pm


Return to Tecfidera (BG-12, dimethyl fumarate)

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service